Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Integrin αIIbβ3 inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia
Other Titles: Integrin alphaIIb beta3 inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia
Author: Abumiya, T.
Fitridge, R.
Mazur, C.
Copeland, B.
Koziol, J.
Tschopp, J.
Pierschbacher, M.
del Zoppo, G.
Citation: Stroke, 2000; 31(6):1402-1410
Publisher: Lippincott Williams & Wilkins
Issue Date: 2000
ISSN: 0039-2499
Statement of
Takeo Abumiya, Robert Fitridge, Curt Mazur, Brian R. Copeland, James A. Koziol, Juerg F. Tschopp, Michael D. Pierschbacher, Gregory J. del Zoppo, and Patricia D. Hurn
Abstract: <h4>Background and purpose</h4>Platelets become activated and accumulate in brain microvessels of the ischemic microvascular bed after experimental focal cerebral ischemia. The binding of glycoprotein IIb/IIIa (integrin alpha(IIb)beta(3)) on platelets to fibrinogen is the terminal step in platelet adhesion and aggregation. This study tests the hypothesis that inhibition of platelet-fibrin(ogen) interactions may prevent microvascular occlusion after experimental middle cerebral artery occlusion (MCA:O).<h4>Methods</h4>TP9201 is a novel Arg-Gly-Asp (RGD)-containing integrin alpha(IIb)beta(3) inhibitor. Microvascular patency after 3-hour MCA:O and 1-hour reperfusion within the ischemic and nonischemic basal ganglia was compared in adolescent male baboons who received high-dose TP9201 (group A: IC(80) in heparin, n=4), low-dose TP9201 (group B: IC(30) in heparin, n=4), or no treatment (group C: n=4) before MCA:O.<h4>Results</h4>After MCA:O, microvascular patency decreased significantly in group C. However, in the ischemic zones of groups A and B compared with group C, patencies were significantly greater in the 4.0- to 7. 5-microm-diameter (capillary) and 7.5- to 30.0-microm-diameter vessels (2P<0.05). A dose-dependent increase in hemorrhagic transformation was seen in group A (3 of 4 animals) compared with group B (1 of 4 animals), and no hemorrhage was visible in group C (chi(2) analysis for trend, P<0.05).<h4>Conclusions</h4>Platelet activation contributes significantly to ischemic microvascular occlusion. Occlusion formation may be prevented by this RGD-integrin alpha(IIb)beta(3) inhibitor at a dose that does not produce clinically significant parenchymal hemorrhage. The effect of microvascular patency on neuron recovery can now be tested.
Keywords: Microcirculation
Basal Ganglia
Brain Ischemia
Infarction, Middle Cerebral Artery
Cerebral Hemorrhage
Peptides, Cyclic
Platelet Glycoprotein GPIIb-IIIa Complex
Platelet Aggregation Inhibitors
Drug Evaluation, Preclinical
Platelet Activation
Vascular Patency
Dose-Response Relationship, Drug
DOI: 10.1161/01.STR.31.6.1402
Appears in Collections:Aurora harvest 2
Surgery publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.